Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PastoCovac vaccination after autologous stem cell transplantation
IRCT20140818018842N23Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Apr 2022
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PastoCovac in coronavirus disease 2019 (COVID-19), sponsored by Tehran University of Medical Sciences. Primary endpoint: Primary immunologic response. Started Apr 2022; status: completed.
02
Drugs
PastoCovac
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20140818018842N23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20140818018842N23.